Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) EBIT (2024 - 2026)

Kura Oncology has reported EBIT over the past 3 years, most recently at -$78.8 million for Q1 2026.

  • Quarterly EBIT fell 21.82% to -$78.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$20.5 million through Mar 2026, up 88.98% year-over-year, with the annual reading at -$303.6 million for FY2025, 57.16% down from the prior year.
  • EBIT was -$78.8 million for Q1 2026 at Kura Oncology, down from $197.8 million in the prior quarter.
  • Over five years, EBIT peaked at $197.8 million in Q4 2025 and troughed at -$78.8 million in Q1 2026.
  • The 3-year median for EBIT is -$54.0 million (2024), against an average of -$28.4 million.
  • The largest YoY upside for EBIT was 1277.58% in 2025 against a maximum downside of 36.54% in 2025.
  • A 3-year view of EBIT shows it stood at -$16.8 million in 2024, then skyrocketed by 1277.58% to $197.8 million in 2025, then plummeted by 139.85% to -$78.8 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's EBIT are -$78.8 million (Q1 2026), $197.8 million (Q4 2025), and -$73.7 million (Q3 2025).